BPC-157 and the 503A Bulks List: FDA's Review and the July 2026 PCAC Vote

Update (October 2026): At the July 23, 2026 meeting, the Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulks List, going against the FDA staff proposal. The vote is advisory: BPC-157 is not on the 503A Bulks List until FDA completes notice-and-comment rulemaking, which is expected to run into 2027, and FDA can still decline to list it. For current status, see our FDA Peptide Status Tracker.

The Short Answer

At the July 23, 2026 PCAC meeting, FDA proposed that BPC-157 (free base) and BPC-157 acetate not be added to the 503A Bulks List. The nomination — later withdrawn by the nominators, though FDA proceeded anyway — had sought BPC-157 for ulcerative colitis (UC), Crohn's disease, celiac disease, and tendonitis. FDA's briefing package concluded the evidence did not support inclusion across every criterion it weighed.

What BPC-157 Is

BPC-157 is described in the literature as a pentadecapeptide — a 15-amino-acid fragment of a protein called Body Protection Compound (BPC) first described in 1993 and characterized as a possible endogenous free-radical scavenger and organoprotective mediator. It is most commonly marketed for gastrointestinal and tissue-repair uses (tendon, ligament, and wound healing). For background on how peptides like this move through the compounding system, see our peptide therapy primer and BPC peptide page.

Characterization: "Not Well-Characterized"

FDA concluded that both the free base and acetate forms are not well-characterized physically and chemically, citing (1) inconsistent naming conventions that do not follow established nomenclature standards (USAN, INN, IUPAC), and (2) missing substance-specific quality-control data. The literature reports BPC-157 as stable only under deep-freeze storage (below roughly −18 to −20°C), and critical attributes needed to establish identity, strength, quality, and purity were not consistently available.

Effectiveness: One Small Abstract Isn't Enough

For the lead nominated indication — ulcerative colitis — FDA found a lack of evidence of effectiveness. There has been only a single small trial of BPC-157 in UC, and interpretation was limited by sparse detail in the meeting abstract and the study's exploratory nature. FDA identified no studies administering BPC-157 by the oral, subcutaneous, nasal, or transdermal routes in UC patients. For the other proposed uses (Crohn's, celiac, tendonitis), the agency found the effectiveness evidence similarly insufficient, and it noted multiple FDA-approved products already exist to treat UC.

Safety: Preclinical Signals, No Human Profile

FDA acknowledged nonclinical (animal) studies in which BPC-157-related substances appeared to prevent colonic fistulas and hepatic and GI lesions, with hypothesized mechanisms involving up-regulation of growth factors, suppression of inflammatory factors, angiogenesis, and nitric-oxide synthesis. But it stressed that dose-response relationships were not established and that there is insufficient clinical safety information to characterize BPC-157's human safety profile — with no studies administering it to humans by the proposed routes. As an injectable peptide, it also raises unassessed immunogenicity risk.

What It Means for Physicians

BPC-157 was not FDA-approved before this review and is not now. Because it has no USP monograph and is not a component of an approved drug, the 503A Bulks List was the pathway in question — and FDA is proposing to keep it closed. Read this alongside the pillar overview of the July 2026 PCAC decision, and confirm current sourcing with your 503A compounding partner.

Key Takeaways

• FDA is proposing that BPC-157 (free base and acetate) not join the 503A Bulks List.
• Cited reasons: not well-characterized, lack of effectiveness evidence for UC and other uses, and insufficient human safety data.
• Animal data are suggestive but lack dose-response and human confirmation.
• This is an advisory-committee proposal, not a final ban; BPC-157 remains non-FDA-approved.

Frequently Asked Questions

Is BPC-157 banned by the FDA?
No. FDA is proposing that BPC-157 not be added to the 503A Bulks List. That is an advisory-committee proposal, not a final determination, and BPC-157 was never FDA-approved.

What was BPC-157 nominated to treat?
Ulcerative colitis, Crohn's disease, celiac disease, and tendonitis. FDA focused its effectiveness review on ulcerative colitis and found the evidence insufficient.

Why does FDA say BPC-157 is "not well-characterized"?
Because of inconsistent chemical naming and missing substance-specific quality data — impurity, aggregate, endotoxin, and bioburden information needed to control identity and purity was not available in the public literature.

Does BPC-157 have human safety data?
FDA concluded there is insufficient clinical safety information to characterize its human safety profile, and found no studies administering it to humans by the proposed routes.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.